Vanda Pharmaceuticals
VNDA
141 hedge funds and large institutions have $648M invested in Vanda Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 63 increasing their positions, 48 reducing their positions, and 15 closing their positions.
92.47% more ownership
Funds ownership: 0% → 92.47% (+92%)
31% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 48
27% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 15
10% more call options, than puts
Call options by funds: $15M | Put options by funds: $13.6M
1% more funds holding
Funds holding: 140 → 141 (+1)
3% less capital invested
Capital invested by funds: $672M → $648M (-$23.3M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$14.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.5M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$10.9M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$7.46M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$7.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Paulson & Co
New York
|
-$36.2M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$11.2M |
| 3 |
Millennium Management
New York
|
-$10.6M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$7.17M |
| 5 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$6.57M |
VNDA Hedge Fund Activity: Q4 2016 in Review
141 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q4 2016, worth a combined $648M — down 3.5% from $672M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new VNDA positions and 15 closed out — a net gain of 4 holders — while 63 added to existing stakes and 48 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $14.7M. The largest seller was Paulson & Co, exiting entirely with an estimated $36.2M sold.
- 141 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q4 2016, up from 140 in Q3 2016.
- Funds reported $648M of Vanda Pharmaceuticals stock for Q4 2016, down 3.5% quarter-over-quarter.
- 19 funds opened new Vanda Pharmaceuticals positions in Q4 2016 and 15 closed out, a net change of +4 holders.
- The largest Vanda Pharmaceuticals buyer in Q4 2016 was Acadian Asset Management, an estimated $14.7M added.
- The largest Vanda Pharmaceuticals seller in Q4 2016 was Paulson & Co, an estimated $36.2M sold.
Based on aggregated 13F filings for Q4 2016.